Renal and hormonal actions of atrial natriuretic peptide during angiotensin II or noradrenaline infusion in man

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide) and Angiotensin II, published as a controlled clinical trial.

Lithium clearance was used to evaluate segmental tubular reabsorption.

Why It Was Studied

In order to study the renal and hormonal actions of atrial natriuretic peptide (ANP) during background infusions with angiotensin II (ANG II) or noradrenaline (NA), 69 healthy subjects were examined in three main groups receiving a 90-min infusion with either placebo, ANG II (1.5 ng kg-1 min-1), or NA (25 ng kg-1 min-1).

Each of these three main groups were subdivided into two groups receiving an infusion with either placebo or ANP (10 ng kg-1 min-1) for the last 60 min of the background infusion.

Who Took Part

The abstract describes 69 subjects taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a placebo-controlled study.

Some subjects received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Angiotensin II, Atrial Natriuretic Factor, Cyclic GMP, Glomerular Filtration Rate, Hormones, Kidney and Kidney Tubules.

What This Means in Plain Language

The paper is a placebo-controlled study of ANP (Atrial Natriuretic Peptide) and Angiotensin II in 69 subjects.

The publication is from 1996 (European journal of clinical investigation), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page and the Angiotensin II compound page, all human trials.